Drug Type Interferons, Biosimilar |
Synonyms Hanferon, HL-031 (oral interferon alpha-2b)-HanAll Biopharma, HL-143 (subcutaneous interferon alpha-2b)-HanAll Biopharma + [4] |
Target |
Action agonists, stimulants, inducers |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Interferon alfa-2b(Nautilus Biotech SA) | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic hepatitis C genotype 1b | Phase 2 | United States | 23 Jun 2011 | |
| Hepatocellular Carcinoma | Phase 2 | - | - |






